Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Exposure to CARDIovascular Risk Assessed by Cardiac Adiposity in oBese adOlescents Eligible to a Residential Long-term Lifestyle Intervention by Diet and eXercise (CARDIBOX) (CARDIBOX)

perjantai 13. maaliskuuta 2020 päivittänyt: University Hospital, Clermont-Ferrand

Exposure to CARDIovascular Risk Assessed by Cardiac Adiposity in oBese adOlescents Eligible to a Residential Long-term Lifestyle Intervention by Diet and eXercise

The high prevalence of childhood obesity is a major public health issue, worldwide. Childhood obesity is associated with a high risk of cardiovascular events in adulthood, but recent studies also point out the development of cardiovascular complications in childhood or adolescence justifying the need for early detection and appropriate therapeutic management to prevent the development of more severe abnormalities. This project proposes to evaluate the myocardial function in a fine and comprehensive way (longitudinal, circumferential and radial linear deformations, and rotation / torsion mechanics) from the deformation imaging (MRI and high-resolution echocardiography), in obese adolescents following a lifestyle intervention combining diet and physical activity.

Tutkimuksen yleiskatsaus

Yksityiskohtainen kuvaus

The investigators aim to improve knowledge of the association between epicardial adipose tissue, myocardial lipid content, and left ventricular regional myocardial function.

In this protocol, obese adolescents are recruited undergoing a 3-month lifestyle intervention residential program. Adolescents from the intervention group will be enrolled at the obesity center for the whole school year. The obesity center employs a multidisciplinary team to provide the best weight management care to adolescents during their stay. The weight loss program is an integral part of the obesity center program and fundamentally combines physical activity with a normocaloric diet monitored by a dietician. The physical activity program consists of two training sessions (aerobic and resistance training) per week. Moreover, adolescents will be engaged in two additional sessions per week, consisting in recreational activities such as ball and racquet games, trekking, snowshoeing or swimming.

There will be two measurement time: one at baseline (Day 0) and one at three months after the beginning of the lifestyle intervention (M3). The controls will be evaluated at baseline only.

Statistical analysis will be performed using Stata software (version 13; Stata-Corp, College Station, Tex., USA). All statistical tests will be two-sided and p inferior to 0.05 will be considered significant. Qualitative variables will be described in terms of numbers and proportions. Quantitative variables will be described in terms of numbers, mean standard deviation or median according to statistical distribution (normality studied using Shapiro-Wilk test). Graphic representations will be complete presentations of results. The main analysis will be performed with the Stata software (version 13, StataCorp, College Station). All statistical tests will be carried out at a risk of error of first species α set at 5%. Most of the analysis of the secondary evaluation criteria will be exploratory in nature and may lack power in terms of numbers. As discussed by Feise in 2002,104 the adjustment of the risk of error of 1st species will not be systematically proposed, but case by case in view of clinical considerations and not only statistical (e.g. Sidak correction for the analysis of correlation coefficients).

Qualitative variables will be described in terms of numbers and proportions. Quantitative variables will be described in terms of standard deviation or mean median according to statistical distribution (normality studied using Shapiro-Wilk test). Graphic representations will be complete presentations of results.

Intergroup comparisons will be systematically conducted without adjustment and by adjusting for factors whose distribution could be unbalanced between groups. Patients will be described and compared between groups at inclusion according to the following variables: compliance with eligibility criteria, epidemiological characteristics, clinical characteristics and characteristics of possible treatments. The baseline comparability of the two groups will be assessed on the main characteristics of the participants and potential factors associated with the primary outcome. A possible difference between the two groups on one of these characteristics will be determined according to clinical considerations and not solely statistical ones.

Opintotyyppi

Interventio

Ilmoittautuminen (Odotettu)

50

Vaihe

  • Ei sovellettavissa

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskelupaikat

      • Clermont-Ferrand, Ranska, 63000
        • CHU de Clermont-Ferrand

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

12 vuotta - 16 vuotta (Lapsi)

Hyväksyy terveitä vapaaehtoisia

Ei

Sukupuolet, jotka voivat opiskella

Kaikki

Kuvaus

Inclusion Criteria:

  • age between 12 and 16 years old
  • mature (menarche)
  • suitable for physical activity
  • able to give an informative consent
  • affiliated at French insurance company
  • consent from the legal representatives
  • For obese adolescents: BMI greater than the 97th percentile of national curves.
  • For the control group: to be normal-weighted (no obesity if overweight, <85th percentile of national curves).

Exclusion Criteria:

  • Medical or surgical history judged by the investigator as incompatible with the study
  • Drugs that may interfere with the study results
  • Cardiovascular, hepatic, psychiatric, renal, or endocrinological diseases
  • Smoking
  • Alcohol consumption
  • Intense physical activity in competition

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Ennaltaehkäisy
  • Jako: Ei satunnaistettu
  • Inventiomalli: Rinnakkaistehtävä
  • Naamiointi: Ei mitään (avoin tarra)

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Kokeellinen: Obese adolescents
BMI greater than the 97th percentile of national curves. Participants will follow a 3-month lifestyle intervention

Adolescents from the intervention group will be enrolled at the obesity center for the whole school year (i.e., 10 months). The physical activity program consists of two training sessions (aerobic and resistance training) per week.

There will be two measurement time: one at baseline (Day 0) and one at three months after the beginning of the lifestyle intervention (M3). The controls will be evaluated at baseline only.

Ei väliintuloa: Control group
to be normal-weighted (no obesity if overweight, <85th percentile of national curves).

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
cardiac ectopic fat deposits
Aikaikkuna: Month 3
Quantification of cardiac ectopic fat deposits (thickness using echocardiography)
Month 3
cardiac ectopic fat deposits
Aikaikkuna: Day 0
Quantification of cardiac ectopic fat deposits (thickness using echocardiography)
Day 0
cardiac ectopic fat deposits
Aikaikkuna: Day 0
Quantification of cardiac ectopic fat deposits (volume using MRI)
Day 0
cardiac ectopic fat deposits
Aikaikkuna: Month 3
Quantification of cardiac ectopic fat deposits (volume using MRI)
Month 3
cardiac ectopic fat deposits
Aikaikkuna: Month 3
Quantification of cardiac ectopic fat deposits (myocardial triglyceride content evaluated by MRI)
Month 3
cardiac ectopic fat deposits
Aikaikkuna: Day 0
Quantification of cardiac ectopic fat deposits (myocardial triglyceride content evaluated by MRI)
Day 0
left myocardial regional function
Aikaikkuna: Month 3
left myocardial regional function (echocardiography)
Month 3
left myocardial regional function
Aikaikkuna: Month 3
left myocardial regional function (MRI)
Month 3
left myocardial regional function
Aikaikkuna: Day 0
left myocardial regional function (echocardiography)
Day 0
left myocardial regional function
Aikaikkuna: Day 0
left myocardial regional function (MRI)
Day 0

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
macrovascularisation
Aikaikkuna: Day 0
measure of carotid intima-media thickness (CIMT) using High-resolution B-mode ultrasound
Day 0
macrovascularisation
Aikaikkuna: Month 3
measure of carotid intima-media thickness (CIMT) using High-resolution B-mode ultrasound
Month 3
microvascularisation
Aikaikkuna: Month 3
measure of blood flow velocity using laser speckle contrast imaging (LSCI)
Month 3
microvascularisation
Aikaikkuna: Day 0
measure of blood flow velocity using laser speckle contrast imaging (LSCI)
Day 0
microvascularisation
Aikaikkuna: Day 0
measure of microvascular perfusion using laser-Doppler flowmetry (LDF)
Day 0
microvascularisation
Aikaikkuna: Month 3
measure of microvascular perfusion using laser-Doppler flowmetry (LDF)
Month 3
microvascularisation
Aikaikkuna: Month 3
measure of microvascular perfusion using Iontophoresis procedure
Month 3
microvascularisation
Aikaikkuna: Day 0
measure of microvascular perfusion using Iontophoresis procedure
Day 0
microvascularisation
Aikaikkuna: Day 0
measure of microvascular perfusion using flowmotion
Day 0
microvascularisation
Aikaikkuna: Month 3
measure of microvascular perfusion using flowmotion
Month 3
heart rate variability
Aikaikkuna: Month 3
measure of heart rate variability using a holter
Month 3
heart rate variability
Aikaikkuna: Day 0
measure of heart rate variability using a holter
Day 0
skin conductance
Aikaikkuna: Day 0
measure of skin conductance using Wristband electrodes - Empatica E4
Day 0
skin conductance
Aikaikkuna: Month 3
measure of skin conductance using Wristband electrodes - Empatica E4
Month 3
Liver steatosis
Aikaikkuna: Month 3
measure of liver steatosis by MRI
Month 3
Liver steatosis
Aikaikkuna: Day 0
measure of liver steatosis by MRI
Day 0
Liver steatosis
Aikaikkuna: Day 0
measure of liver steatosis by fibroscanner (ultrasonic attenuation)
Day 0
Liver steatosis
Aikaikkuna: Month 3
measure of liver steatosis by fibroscanner (ultrasonic attenuation)
Month 3
Liver steatosis
Aikaikkuna: month 3
measure of liver steatosis by Aixplorer (Lipersonic Imagine®)
month 3
Liver steatosis
Aikaikkuna: Day 0
measure of liver steatosis by Aixplorer (Lipersonic Imagine®)
Day 0
Liver fibrosis
Aikaikkuna: Day 0
measure of liver fibrosis by fibroscanner (liver stiffness)
Day 0
Liver fibrosis
Aikaikkuna: Month 3
measure of liver fibrosis by fibroscanner (liver stiffness)
Month 3
Liver fibrosis
Aikaikkuna: Month 3
measure of liver fibrosis by fibrotest (Lipersonic Imagine®)
Month 3
Liver fibrosis
Aikaikkuna: Day 0
measure of liver fibrosis by fibrotest (Lipersonic Imagine®)
Day 0
blood pressure
Aikaikkuna: Day0
measure of blood pressure using sphygmomanometer
Day0
blood pressure
Aikaikkuna: month 3
measure of blood pressure using sphygmomanometer
month 3
Fitness
Aikaikkuna: Month 3
6-minutes walking test to assess functional capacity at a sub-maximal level, and the effects of exercise training in cardiac and pulmonary patients.
Month 3
Fitness
Aikaikkuna: Day 0
6-minutes walking test to assess functional capacity at a sub-maximal level, and the effects of exercise training in cardiac and pulmonary patients.
Day 0
muscle mass
Aikaikkuna: Month 3
measure of muscle mass using impedancemeter
Month 3
fat mass
Aikaikkuna: Month 3
measure of muscle mass using impedancemeter
Month 3
bone structure
Aikaikkuna: Month 3
measure of muscle mass using impedancemeter
Month 3
muscle mass
Aikaikkuna: Day 0
measure of muscle mass using impedancemeter
Day 0
fat mass
Aikaikkuna: Day 0
measure of muscle mass using impedancemeter
Day 0
bone structure
Aikaikkuna: Day 0
measure of muscle mass using impedancemeter
Day 0
muscle mass
Aikaikkuna: Day 0
measure of muscle mass using Densitometry X-ray absorption
Day 0
fat mass
Aikaikkuna: Day 0
measure of muscle mass using Densitometry X-ray absorption
Day 0
bone structure
Aikaikkuna: Day 0
measure of muscle mass using Densitometry X-ray absorption
Day 0
muscle mass
Aikaikkuna: Month 3
measure of muscle mass using Densitometry X-ray absorption
Month 3
fat mass
Aikaikkuna: Month 3
measure of muscle mass using Densitometry X-ray absorption
Month 3
bone structure
Aikaikkuna: Month 3
measure of muscle mass using Densitometry X-ray absorption
Month 3
muscle mass
Aikaikkuna: Month 3
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Month 3
fat mass
Aikaikkuna: Month 3
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Month 3
bone structure
Aikaikkuna: Month 3
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Month 3
muscle mass
Aikaikkuna: Day 0
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Day 0
fat mass
Aikaikkuna: Day 0
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Day 0
bone structure
Aikaikkuna: Day 0
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Day 0
muscle mass
Aikaikkuna: Day 0
measure of muscle mass using Quantitative ultrasounds (QUS)
Day 0
fat mass
Aikaikkuna: Day 0
measure of muscle mass using Quantitative ultrasounds (QUS)
Day 0
bone structure
Aikaikkuna: Day 0
measure of muscle mass using Quantitative ultrasounds (QUS)
Day 0
muscle mass
Aikaikkuna: Month 3
measure of muscle mass using Quantitative ultrasounds (QUS)
Month 3
fat mass
Aikaikkuna: Month 3
measure of muscle mass using Quantitative ultrasounds (QUS)
Month 3
bone structure
Aikaikkuna: Month 3
measure of muscle mass using Quantitative ultrasounds (QUS)
Month 3
depression
Aikaikkuna: Day 0
depression is assessed by the Hospital Anxiety and Depression scale (HAD) composed by 7 items and a 4-point scale from "never" to "always".
Day 0
depression
Aikaikkuna: Month 3
depression is assessed by the Hospital Anxiety and Depression scale (HAD) composed by 7 items and a 4-point scale from "never" to "always".
Month 3
anxiety
Aikaikkuna: Day 0
anxiety is assessed by the Hospital Anxiety and Depression scale (HAD) composed by 7 items and a 4-point scale from "never" to "always". It is also evaluated by the State-Trait Anxiety Inventory (STAI) composed by two dimensions, state anxiety and trait anxiety, both evaluated with a 20-items questionnaire on a 4-point scale from "never" to "always"
Day 0
anxiety
Aikaikkuna: Month 3
anxiety is assessed by the Hospital Anxiety and Depression scale (HAD) composed by 7 items and a 4-point scale from "never" to "always". It is also evaluated by the State-Trait Anxiety Inventory (STAI) composed by two dimensions, state anxiety and trait anxiety, both evaluated with a 20-items questionnaire on a 4-point scale from "never" to "always"
Month 3
General health
Aikaikkuna: Day 0
general health is assessed by the short form 36 health survey (SF36) composed by 36 items
Day 0
General health
Aikaikkuna: Month 3
general health is assessed by the short form 36 health survey (SF36) composed by 36 items
Month 3
Stress
Aikaikkuna: day 0
stress is assessed by a Visuel analog scale of 100mm ranging from very low (0) to very high (100)
day 0
Stress
Aikaikkuna: Month 3
stress is assessed by a Visuel analog scale of 100mm ranging from very low (0) to very high (100)
Month 3
Fatigue
Aikaikkuna: Day 0
Fatigue is assessed by a Visuel analog scale of 100mm ranging from very low (0) to very high (100)
Day 0
Fatigue
Aikaikkuna: Month 3
Fatigue is assessed by a Visuel analog scale of 100mm ranging from very low (0) to very high (100)
Month 3
Sleep
Aikaikkuna: day 0
Burnout is assessed by the Maslach Burn-out Inventory (MBI) composed by 22 items and a 7-point scale ranging from "never" to "every day".
day 0
Sleep
Aikaikkuna: Month 3
Burnout is assessed by the Maslach Burn-out Inventory (MBI) composed by 22 items and a 7-point scale ranging from "never" to "every day".
Month 3
Burnout
Aikaikkuna: day 0
Burnout is assessed by the Maslach Burn-out Inventory (MBI) composed by 22 items and a 7-point scale ranging from "never" to "every day".
day 0
Burnout
Aikaikkuna: Month 3
Burnout is assessed by the Maslach Burn-out Inventory (MBI) composed by 22 items and a 7-point scale ranging from "never" to "every day".
Month 3
Mindfulness
Aikaikkuna: Day 0
Midfuless is assessed by the Freiburg Mindfulness Inventory-14 (FMI) composed by a 4-point Likert scale ranging from 1 (strongly disagree) to 4 (strongly agree)
Day 0
Mindfulness
Aikaikkuna: Month 3
Midfuless is assessed by the Freiburg Mindfulness Inventory-14 (FMI) composed by a 4-point Likert scale ranging from 1 (strongly disagree) to 4 (strongly agree)
Month 3
Coping
Aikaikkuna: Day 0
Coping is assessed by the Brief Illness Perception Questionnaire (B-IPQ) composed by an 11-point scale
Day 0
Coping
Aikaikkuna: Month 3
Coping is assessed by the Brief Illness Perception Questionnaire (B-IPQ) composed by an 11-point scale
Month 3
Emotions
Aikaikkuna: Day 0
Emotions are assessed by the Emotion Régulation Questionnaire (ERQ) composed by 10 items on a 7-point likert scale ranging from 1 (strongly disagree) to 7 (strongly agree)
Day 0
Emotions
Aikaikkuna: Month 3
Emotions are assessed by the Emotion Régulation Questionnaire (ERQ) composed by 10 items on a 7-point likert scale ranging from 1 (strongly disagree) to 7 (strongly agree)
Month 3
Perception of work
Aikaikkuna: Day 0
Work perception is assessed by the Job Demand-Control-Support (JDSC) questionnaire of Karasek composed by 26 items on a 4-point scale ranging from 1 (strongly disagree) to 4 (strongly agree). It is also evaluated by the effort-reward imbalance model (ERI) of Siegrist composed by 46 items on a 5-point scale ranging from 1 (no agreement) to 5 (agree and very disturb).
Day 0
Perception of work
Aikaikkuna: Month 3
Work perception is assessed by the Job Demand-Control-Support (JDSC) questionnaire of Karasek composed by 26 items on a 4-point scale ranging from 1 (strongly disagree) to 4 (strongly agree). It is also evaluated by the effort-reward imbalance model (ERI) of Siegrist composed by 46 items on a 5-point scale ranging from 1 (no agreement) to 5 (agree and very disturb).
Month 3
Self-efficacy
Aikaikkuna: Day 0
Self-efficacy is assessed by the perceived self-efficacy scale composed by 10 items on a 4-point scale
Day 0
Self-efficacy
Aikaikkuna: Month 3
Self-efficacy is assessed by the perceived self-efficacy scale composed by 10 items on a 4-point scale
Month 3
Alexithymia
Aikaikkuna: Day 0
Alexithymia is assessed by the Twenty-item Toronto Alexithymia Scale (TAS20) composed by a 5-point scale from "strongly agree" to "strongly disagree".
Day 0
Alexithymia
Aikaikkuna: Month 3
Alexithymia is assessed by the Twenty-item Toronto Alexithymia Scale (TAS20) composed by a 5-point scale from "strongly agree" to "strongly disagree".
Month 3
Illness perception
Aikaikkuna: Day 0
Perception of illness is assessed by the Brief Illness Perception Questionnaire (B-IPQ) composed by a 11-point scale.
Day 0
Illness perception
Aikaikkuna: Month 3
Perception of illness is assessed by the Brief Illness Perception Questionnaire (B-IPQ) composed by a 11-point scale.
Month 3
Metacognition
Aikaikkuna: Day 0
Metacognition is assessed by the MetaCognition Questionnaire (MCQ-30) composed by 30 items on a 5-point scale
Day 0
Metacognition
Aikaikkuna: Month 3
Metacognition is assessed by the MetaCognition Questionnaire (MCQ-30) composed by 30 items on a 5-point scale
Month 3
Time perception
Aikaikkuna: Day 0
Perception of the time is assessed by the Metacognitive questionnaire on time perception (MQT) composed by 24 items on a 5-point scale. It is also evaluated by the Zimbardo Time Perspective Inventory (ZPTI) composed by 56 items on a 5-point scale from "very uncharacteristic" to "very characteristic".
Day 0
Time perception
Aikaikkuna: Month 3
Perception of the time is assessed by the Metacognitive questionnaire on time perception (MQT) composed by 24 items on a 5-point scale. It is also evaluated by the Zimbardo Time Perspective Inventory (ZPTI) composed by 56 items on a 5-point scale from "very uncharacteristic" to "very characteristic".
Month 3
Physical activity
Aikaikkuna: Day 0
Physical activity is assessed by the Recent Physical Activity Questionnaire (RPAQ)
Day 0
Physical activity
Aikaikkuna: Month 3
Physical activity is assessed by the Recent Physical Activity Questionnaire (RPAQ)
Month 3
Life style
Aikaikkuna: Day 0
life style is assessed with a questionnaire on coffee consumption, food intake, etc
Day 0
Life style
Aikaikkuna: Month 3
life style is assessed with a questionnaire on coffee consumption, food intake, etc
Month 3
cholesterol
Aikaikkuna: Day 0
measure by blood analyses to evaluate alloplastic load
Day 0
triglycerides
Aikaikkuna: Day 0
measure by blood analyses to evaluate alloplastic load
Day 0
cholesterol
Aikaikkuna: Month 3
measure by blood analyses to evaluate alloplastic load
Month 3
triglycerides
Aikaikkuna: Month 3
measure by blood analyses to evaluate alloplastic load
Month 3
Cortisol
Aikaikkuna: Day 0
hormone measure by blood analyses to evaluate alloplastic load
Day 0
Cortisol
Aikaikkuna: Month 3
hormone measure by blood analyses to evaluate alloplastic load
Month 3
DHEAS
Aikaikkuna: day 0
hormone measure by blood analyses to evaluate alloplastic load
day 0
DHEAS
Aikaikkuna: Month 3
hormone measure by blood analyses to evaluate alloplastic load
Month 3
BDNF
Aikaikkuna: Day 0
proteins measure by blood analyses to evaluate alloplastic load
Day 0
BDNF
Aikaikkuna: Month 3
proteins measure by blood analyses to evaluate alloplastic load
Month 3
CRP
Aikaikkuna: Day 0
proteins measure by blood analyses to evaluate alloplastic load
Day 0
pro-inflammatory cytokines
Aikaikkuna: Day 0
proteins measure by blood analyses to evaluate alloplastic load
Day 0
TNF alpha
Aikaikkuna: Day 0
proteins measure by blood analyses to evaluate alloplastic load
Day 0
CRP
Aikaikkuna: Month 3
proteins measure by blood analyses to evaluate alloplastic load
Month 3
pro-inflammatory cytokines
Aikaikkuna: Month 3
proteins measure by blood analyses to evaluate alloplastic load
Month 3
TNF alpha
Aikaikkuna: Month 3
proteins measure by blood analyses to evaluate alloplastic load
Month 3
NPY
Aikaikkuna: Month 3
proteins measure by blood analyses to evaluate alloplastic load
Month 3
NPY
Aikaikkuna: Day 0
proteins measure by blood analyses to evaluate alloplastic load
Day 0
Leptin
Aikaikkuna: Day 0
measure by blood analyses to evaluate appetite regulation
Day 0
Leptin
Aikaikkuna: Month 3
measure by blood analyses to evaluate appetite regulation
Month 3
Ghrelin
Aikaikkuna: Day 0
measure by blood analyses to evaluate appetite regulation
Day 0
Ghrelin
Aikaikkuna: Month 3
measure by blood analyses to evaluate appetite regulation
Month 3
NPY
Aikaikkuna: day 0
measure by blood analyses to evaluate appetite regulation
day 0
NPY
Aikaikkuna: Month 3
measure by blood analyses to evaluate appetite regulation
Month 3
adiponectine
Aikaikkuna: Day 0
measure by blood analyses to evaluate appetite regulation
Day 0
adiponectine
Aikaikkuna: Month 3
measure by blood analyses to evaluate appetite regulation
Month 3
CCK
Aikaikkuna: Day 0
measure by blood analyses to evaluate appetite regulation
Day 0
Month 3
Aikaikkuna: Day 0
measure by blood analyses to evaluate appetite regulation
Day 0
Insulin
Aikaikkuna: Day 0
measure by blood analyses to evaluate glucid metabolism
Day 0
Insulin
Aikaikkuna: Month 3
measure by blood analyses to evaluate glucid metabolism
Month 3
HbA1c
Aikaikkuna: Day 0
measure by blood analyses to evaluate glucid metabolism
Day 0
HbA1c
Aikaikkuna: Month 3
measure by blood analyses to evaluate glucid metabolism
Month 3
glucose
Aikaikkuna: Day 0
measure by blood analyses to evaluate glucid metabolism
Day 0
glucose
Aikaikkuna: Month 3
measure by blood analyses to evaluate glucid metabolism
Month 3
Albumin
Aikaikkuna: Day 0
measure by blood analyses to evaluate protid metabolism
Day 0
Albumin
Aikaikkuna: Month 3
measure by blood analyses to evaluate protid metabolism
Month 3
transthyretin
Aikaikkuna: Day 0
measure by blood analyses to evaluate protid metabolism
Day 0
transthyretin
Aikaikkuna: Month 3
measure by blood analyses to evaluate protid metabolism
Month 3
Homeostasis
Aikaikkuna: Day 0
measure of Fibroblast growth factor 23 (FGF23) by blood analyses to evaluate bone metabolism
Day 0
Homeostasis
Aikaikkuna: Month 3
measure of Fibroblast growth factor 23 (FGF23) by blood analyses to evaluate bone metabolism
Month 3
Osteoresorption
Aikaikkuna: Day 0
measure of C-terminal Telopeptide of Type I collagen (CTx) by blood analyses to evaluate bone metabolism
Day 0
Osteoresorption
Aikaikkuna: Month 3
measure of C-terminal Telopeptide of Type I collagen (CTx) by blood analyses to evaluate bone metabolism
Month 3
Osteoformation
Aikaikkuna: Day 0
measure of decarboxylated osteocalcine and BSAP by blood analyses to evaluate bone metabolism
Day 0
Osteoformation
Aikaikkuna: Month 3
measure of decarboxylated osteocalcine and BSAP by blood analyses to evaluate bone metabolism
Month 3
VEGF
Aikaikkuna: Day 0
measure by blood analyses to evaluate cardiovascular function
Day 0
VEGF
Aikaikkuna: Month 3
measure by blood analyses to evaluate cardiovascular function
Month 3
PAI1
Aikaikkuna: Day 0
measure by blood analyses to evaluate cardiovascular function
Day 0
PAI1
Aikaikkuna: Month 3
measure by blood analyses to evaluate cardiovascular function
Month 3
weight
Aikaikkuna: Day 0
measure of weight in kilograms
Day 0
weight
Aikaikkuna: Month 3
measure of weight in kilograms
Month 3
waist circumference
Aikaikkuna: Day 0
measure of waist circumference in centimetres
Day 0
waist circumference
Aikaikkuna: Month 3
measure of waist circumference in centimetres
Month 3

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Odotettu)

Tiistai 1. syyskuuta 2020

Ensisijainen valmistuminen (Odotettu)

Tiistai 1. kesäkuuta 2021

Opintojen valmistuminen (Odotettu)

Tiistai 1. kesäkuuta 2021

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Maanantai 10. helmikuuta 2020

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Perjantai 13. maaliskuuta 2020

Ensimmäinen Lähetetty (Todellinen)

Tiistai 17. maaliskuuta 2020

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Tiistai 17. maaliskuuta 2020

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Perjantai 13. maaliskuuta 2020

Viimeksi vahvistettu

Lauantai 1. helmikuuta 2020

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Muut tutkimustunnusnumerot

  • RBHP 2019 DUTHEIL
  • 2019-A01804-53 (Muu tunniste: ANSM)

Yksittäisten osallistujien tietojen suunnitelma (IPD)

Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?

Päättämätön

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Ei

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Yhdysvalloissa valmistettu ja sieltä viety tuote

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa